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Sedaxicenes: potential new antifungal
ferrocene-based agents?†
R. Rubbiani,* O. Blacque and G. Gasser*
Fungal infections are a group of diseases spread all over the world with an extremely high morbidity.
Worryingly, although several pathogenic fungi were found to develop resistance towards traditional
therapy, research towards the discovery of novel antimycotic agents is very limited. Considering the
promising results obtained with the ferrocene-based drug candidates Ferroquine and Ferrocifen as anti-
malarial and anticancer drug candidates, respectively, we envisaged derivatizing the organic scaﬀold of a
new broad-spectrum fungicide, namely sedaxane, with a ferrocenyl moiety in order to obtain new metal-
based antifungal agents. The new ferrocenyl sedaxane derivatives called herein Sedaxicenes (1a, 2 and 3)
were characterized using diﬀerent analytical techniques and the structures were conﬁrmed by X-ray
crystallography. As expected for antimycotic agents, 1a, 2 and 3 were found to have a low or even no tox-
icity towards human cells (IC50 > 100 μM). Interestingly, while the parent drug did not display any myco-
toxicity (EC50 > 100 μM), complex 1a was found to have some antifungal activity with an IC50 value of
43 µM under the same experimental conditions. In order to investigate the possible redox-mediated
mode of action of 1a, we synthesized the ruthenocene analogue of 1a, namely 1b. Ruthenocene is
known to have a completely diﬀerent electrochemical behaviour from ferrocene although both the com-
pounds are isostructural. As anticipated, complex 1a was found to induce an increase of the reactive
oxygen species level in S. cerevisiae, contrary to its 1b analogue and to the parent compound sedaxane.
Introduction
Fungal infections are provoked by tiny parasites present in
water, soil, plants, invertebrates and mammals called fungi.1
Fungi belong to a broad family of eukaryotes which display
features at the crossroads between mammalian cells and
bacteria.2–4 Like eukaryotes, they possess the genetic material
located in the nucleus, mitochondria, an endoplasmic reticu-
lum and a digestion vacuole system. Similar to bacteria, they
are a spore-producing microorganism.2–4 Fungi also have a
characteristic cell wall responsible for nutrient traﬃcking with
the host or the environment and with a protective function.5
Despite their limited mortality (<10 million per year), fungi
displayed a very alarming morbidity.6 For example, the lifetime
incidence of candidiasis (fungal infections provoked by the
Candida yeast family) in women reaches 75% and the recent
data showed that 25% of the whole world population is
aﬀected by Tinea pedis (a mold responsible for the “ringworm
of the foot”).6 This represents several hundred millions of
infections per year, a number comparable to those of serious
pathologies like malaria (data of the World Health Organiz-
ation, WHO, updated December 2014). Notably, new diseases
linked to new human life conditions (e.g. diabetes, obesity,
cancer) enable pathogenic fungi to cause severe complications.
Fungal infections are therefore involved in the worsening of
other diseases, impacting the economic system of diﬀerent
nations. In the worst cases, they lead to human death.7 Sur-
prisingly, conventional therapies against fungi rely on a very
limited number of drugs. These therapeutic agents were dis-
covered in the last century and just 7 of them are nowadays in
the list of WHO – Essential Medicine (data of October 2013).8
Moreover, antifungal research is stagnant, especially if com-
pared to other pathologies. In the last few decades, just a few
new antifungal agents have been unveiled and they were
mainly based on structural modifications of the already discov-
ered active drugs. Worryingly, there have recently been an
increasing number of reports showing that diﬀerent pathologi-
†Electronic supplementary information (ESI) available: Analytical data and
crystal representation of 1a, 2 and 3 (Fig. S1–S5); crystal data refinement and
bond/angle calculations for complex 1 (Tables S1–S7); crystal data refinement
and bond/angle calculations for complex 2 (Tables S9–S118); crystal data refine-
ment and bond/angle calculations for complex 3 (Tables S19–S22); general
crystal experiment settings and an example of antifungal toxicity in a 12-well
plate (Fig. S6). CCDC 1433288–1433290. For ESI and crystallographic data in CIF
or other electronic format see DOI: 10.1039/c5dt04231c
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cal fungal strains are developing resistance against convention-
al therapy.9 This alarming observation is a strong incentive for
the discovery of novel compounds or strategies to fight this
clearly underestimated problem.
Research on the medicinal potential of metal complexes
has witnessed a very rapid growth in the last few decades. Plati-
num- and gadolinium-based compounds are nowadays heavily
used as anticancer and imaging agents, respectively. Other
metal complexes like Ferroquine (containing iron) or KP1339
(containing ruthenium) are in clinical trials.10 The reason
behind this “success story” is that metal complexes present
very favourable features, which make them, in some cases,
superior to organic compounds. For example, metal complexes
display an enhanced stereochemistry and reactivity compared
with organic molecules and can have a large repertoire of
physico-chemical properties (lipophilicity, redox potential,
etc.).10,11 Surprisingly, there are only a limited number of
studies on the activity of metal complexes [Co(II), Ni(II), Cu(II),
Mn(I), Pd(II) Bi(III) complexes made a variety of ligands (e.g.
azole moieties, thiosemicarbazones, carboxamides, indoles)]
against fungal strains, hence leaving this very field pretty much
unexplored.12 Due to the encouraging results obtained by many
research groups on the biological potential of metallocenes,12,13
we recently embarked on a project to design novel metal-based
antifungal agents. The synthesis, characterisation and biological
evaluation of three new organometallic complexes based on a
known fungicide are herein reported.
Results and discussion
Drug design
Recently, a potent broad-spectrum fungicide, namely sedaxane
(ISO common name, CAS no. 874967-67-6, see Scheme 1 for
chemical structure), was approved as a pesticide.15 Sedaxane
eﬃciently inhibits the fungal enzyme succinate dehydrogenase
involved in the fungal oxidative phosphoryalation.15 Of utmost
interest is the fact that sedaxane displayed low toxicity and
good clearance, with the majority of the drug excreted within
24 h (in mice models). Moreover, no oral, inhaling or dermal
toxicity was observed for concentrations below 5 g per kg per
day.14 Interestingly, there are no studies on the possible appli-
cation of sedaxane to fight human fungal infections.
Motivated by the work of several research groups which
derivatized a known drug with a ferrocenyl moiety to obtain a
synergistic increase in activity (e.g. Ferrocifen, Ferroquine,
ferrocenyl praziquantel, ferrocenyl platensimycin, etc.),10,11 we
envisaged coupling the favourable therapeutic profile of sedax-
ane with the potential of the ferrocenyl group (see
Scheme 1).12,13
In this work, the core of sedaxane was modified at the bi-
cycloprop-2-yl group, replacing it with a methylferrocene
moiety. This replacement was assumed to not influence the
overall bioactivity, which is hypothesized to be carried out by
the pyrazole carboxamide group by interacting with the iron
cluster of the active site of the enzyme.14 Additionally, the pres-
ence of the ferrocenyl group was anticipated to aﬀord a poten-
tial synergistic mode(s) of action due to the presence of a
redox moiety. It was, for example, demonstrated by Biot and
co-workers that the presence of the ferrocenyl moiety in Ferro-
quine was allowing for the formation of •OH. Since chloro-
quine cannot produce •OH, this radical generation was
assumed to be responsible for the activity of Ferroquine on
chloroquine-resistant parasite strains.12,13 To further confirm
the contribution of redox activity to the overall antifungal
profile of our ferrocenyl derivatives, we synthesized a rutheno-
cenyl sedaxane analogue (1b, see Scheme 1). Ruthenocene is
isostructural to ferrocene but has a significantly diﬀerent
electrochemical behaviour. This diﬀerence was shown in the
past to play an important role in the formation or not of ROS
by Biot and co-workers (e.g. the ruthenocene analogue of Fer-
roquine, namely Ruthenoquine was not producing ROS while
Ferroquine was).13 Of note is that diﬀerent alkylic moieties
were also inserted into the pyrazole core to have a small struc-
ture activity relationship (SAR) study.
Synthetic procedures
The synthesis of the metallocenyl analogues of sedaxane, that
we have named sedaxicenes, was performed according to the
established protocols (see Scheme 2).16 The products 1a, 1b, 2
and 3 were all obtained in moderate yields (23–58%). The new
Scheme 1 Structures of sedaxane and sedaxicenes. The role of each
unit in the molecules is described.
Scheme 2 Synthesis of the new antifungal ferrocenyl drug candidates;
(i) NH2OH in EtOH under reﬂux for 4 h; (ii) LiAlH4 in THF under reﬂux for
3 h, (iii) DIPEA, HATU in DMF at room temperature for 24 h.
Paper Dalton Transactions
6620 | Dalton Trans., 2016, 45, 6619–6626 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
on
 0
8/
02
/2
01
7 
15
:3
4:
40
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
complexes were characterized by 1H, 13C and 19F NMR spectro-
scopy as well as ESI-MS and X-ray diﬀraction studies, and their
purity was assessed by elemental analysis (<0.5% from the cal-
culated value).
The X-ray diﬀraction studies were performed on suitable
single crystals which were obtained after slow evaporation of a
concentrated solution of the complex in chloroform at 25 °C
over a few days. The exemplar perspective view of the mole-
cular structure of complex 1a is shown in Fig. 1 (see the ESI†
for the molecular structures of 2 and 3). Specific features that
confirmed the presence of the products were the disappear-
ance of the acidic proton signal between 12.5 and 13.0 ppm in
the 1H NMR spectra, the up-field shift of the carbonyl carbon
from ∼190 ppm to ∼160 ppm in the 13C NMR spectra, the pres-
ence of a single signal in the 19F NMR spectra and the M+ peak
in the mass spectra.
Host cytotoxicity
With the steady increase of mycoses, antifungal agents are
required to be often administered both topically and systemi-
cally, and to lack therefore host toxicity. In order to investigate
the impact of our sedaxicenes on the host organism, 1a, 2 and
3 were tested for their cytotoxicity against human cells in vitro.
For these experiments, two cells lines were chosen, namely
human fibroblast (MRC-5) and retinal pigment epithelial
(RPE1 hTert), representing both superficial and internal cells,
respectively. The influence of the metal complexes on the cellu-
lar proliferation was aimed to provide important information on
the eﬃcacy of the sedaxicenes as topical as well as systemic drug
candidates. Sedaxane was used as a reference for comparative
purposes and Clotrimazole as a positive control (see Table 1). As
expected, sedaxane did not aﬀect the cell viability. Complexes
1b, 2 and 3 showed a very mild toxicity, in the mid-micromolar
range (towards both the cell lines for 2 and just towards MRC-5
for 1b and towards RPE for 3). Remarkably, complex 1a did not
display any activity towards both cell lines. Interestingly, Clotri-
mazole was found to have a higher cytotoxicity than all sedaxi-
cenes, with IC50 values in the low micromolar range.
Antifungal activity
Once established that the sedaxicenes had no or only minor
toxicity towards human cell lines, the antifungal profile of
these metal complexes was evaluated. Saccharomyces cerevisiae
(SC) was chosen as a valid fungus model for preliminary bio-
logical evaluation.17 The wild type colony of SC was cultured
and diluted to reach the beginning of the growing phase just
before treatment. SC was then seeded at diﬀerent concen-
trations on the agar terrain poured into a 12-well plate and
pre-treated with diﬀerent concentrations of the target sedaxi-
cenes. The plates were then incubated for 24 h at 30 °C and
the colony formation was monitored via an Alpha Digitec
camera with white light excitation. Sedaxane was used in the
study for comparative purposes and Clotrimazole as a positive
control.
Complexes 1a, 2 and 3 were found to reduce the colony for-
mation of SC, displaying moderate IC50 values in the mid-high
micromolar range. Complex 1a, bearing a less hindered pyr-
azole ring in comparison with 2 and 3, was the most active
throughout the series with an EC50 value of 43 μM (see Table 1
and Fig. 2 for an exemplar depicted experiment). Interestingly,
sedaxane as well as 1b did not display any activity up to the
highest concentration used in this study (100 µM).
Reactive oxygen species evaluation
The drug design of the sedaxicenes was based on the insertion
of a ferrocenyl moiety into the known broad-spectrum fungi-
cide sedaxane. The rationale behind this approach is that the
redox iron centre could improve the therapeutic profile of
sedaxane with (an) additional mode(s) of action. Complex 1a
displayed the best antimycotic profile of all compounds tested
Table 1 Antiproliferative eﬀects on non-tumorigenic human ﬁbroblast
and human retinal pigment epithelial cell lines and antifungal activity of
SC seeded on the agar terrain of 1ab–3; sedaxane was used for com-
parative purposes and Clotrimazole as a positive control; values
expressed in IC50/EC50 (µM)
Compound
Human cell lines
S. Cerevisiae
MRC-5 RPE (OD = 0.02)
Clotrimazole 35.8 ± 3.5 13.3 ± 0.6 0.66 ± 0.26
Sedaxane >100 >100 >100
Complex 1a >100 >100 43.3 ± 6.2
Complex 1b 41.0 ± 5.3 >100 >100
Complex 2 48.9 ± 3.1 50.5 ± 7.9 98.6 ± 1.7
Complex 3 >100 67.8 ± 9.4 91.9 ± 3.6
Fig. 2 SC growth inhibition upon treatment with increasing concen-
trations of sedaxane and complex 1a (exemplary ﬁgures concerning 1b,
2, 3 and Clotrimazole are reported in the ESI†); experiment performed at
diﬀerent SC growing indexes (OD = 0.002 and 0.02, respectively).
Fig. 1 X-ray crystal structure of 1a with selective atomic numbering
scheme. Thermal ellipsoids are drawn at the 30% probability level.
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in this study. In order to assess the possible redox activity of
complex 1a, we investigated the rise of the reactive oxygen
species (ROS) level in fungal culture upon treatment with this
compound and compared the data with sedaxane (as parent
drug) and 1b (as redox inactive 1a analogue). For this purpose,
the cell-permeable dye 2′,7′-dichlorofluorescein di-acetate
(H2DCF-DA), which turns to be highly fluorescent upon oxi-
dation in the presence of ROS, was used, as previously
reported by our group for a cytotoxic Au(III) complex.18 Hence,
SC culture was treated for 16 h with 100 µM of complexes 1a
and 1b. The medium was then replaced with fresh YPD (not
containing the metal compounds) treated with H2DCF-DA. The
SC culture was further incubated for 1 h, allowing for the
internalization of the dye before the ROS level was quantified.
Strikingly, the ROS level in SC treated with complex 1a dis-
played an increase of 33% in comparison with the untreated
control (see Fig. 3). This eﬀect was not observed in the case of
1b. SC treated with sedaxane showed a similar ROS level than
the basal value, suggesting that the ferrocenyl moiety is
playing indeed a pivotal role to achieve a valuable fungicidal
profile.
Experimental
General
Chemicals and reagents. All chemicals were of reagent
grade quality or better, obtained from commercial suppliers
and used without further purification. Sedaxane has been pro-
vided by Syngenta AG. Solvents were used as received or dried
over molecular sieves. All preparations were carried out using
standard Schlenk techniques.
Instrumentation and methods. 1H, 19F and 13C NMR
spectra were recorded in deuterated solvents on 400 (1H,
400 MHz; 13C, 100.6 MHz) or 500 (1H, 500 MHz; 13C,
126 MHz) MHz spectrometers at room temperature. The
chemical shifts δ, are reported in ppm (parts per million). The
residual solvent peaks have been used as an internal reference.
The abbreviations for the peak multiplicities and signals
groups are as follows: s (singlet), d (doublet), dd (doublet of
doublets), t (triplet), q (quartet), m (multiplet), br (broad) Ar
(aromatic) and Py (pyrazole). ESI-MS and UPLC-MS were
obtained with a Bruker Esquire 6000 mass spectrometer.
LC-MS and UPLC-MS spectra were recorded on an Acquity
Waters system equipped with a PDA detector and an auto
sampler using an ACQUITY UPLC BEH C18 Gravity 1.7 μm
(2.1 mm × 50 mm) reverse phase column. A total of 2 μL of the
solution was injected into the UPLC that was connected to a
mass spectrometer operated in ESI mode. The UPLC runs
(flow rate 0.6 mL min−1) were performed with a linear gradient
of A (acetonitrile (Sigma-Aldrich HPLC-grade)) and B (distilled
water containing 0.1% formic acid): t = 0–0.25 min, 5% A;
t = 1.5 min, 100% A; t = 5.0 min, 100% A. Elemental micro-
analyses were performed on a LecoCHNS-932 elemental analyser
Synthesis
Methylaminoferrocene. Methylaminoferrocene was syn-
thesized as previously reported.16 Experimental data matched
with the literature reports.
General procedure for synthesis of the sedaxicenes. The
opportune carboxylic acid (0.26 mmol) was dissolved in dry
DMF (2 mL) under a N2 atmosphere. This solution was added
to a 1 mL solution of N,N′-diisopropylethylamine (DIPEA,
0.37 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU)
(0.50 mmol) in dry DMF. The new solution was then stirred for
20 min at room temperature. Methylaminoferrocene (56 mg,
0.26 mmol) dissolved in 10 mL of dry DMF was then added to
the mixture which was then stirred in the dark overnight. The
solvent was evaporated using a high-vacuum pump. The
reddish oil was then purified by column chromatography
(silica, ethylacetate : hexane : acetone, 7 : 2 : 1, Rf = 0.70). The
fractions were collected and the solvent was removed in vacuo
to obtain yellow powder.
N-Methylferrocenyl,3-(trifluoromethyl)-1-methyl-1H-pyrazole-
4-carboxylamide (complex 1a). Yield 46% (47 mg). 1H NMR
(500 MHz), CDCl3, δ (ppm) 7.93 (s, 1H, ArH), 6.20 (s, 1H, NH),
4.23 (m, 12H, FcH/CH2), 3.95 (s, 3H, CH3);
13C NMR
(500 MHz), CDCl3, δ (ppm) 160.5, 136.5, 122.7, 120.6, 117.9,
100.9, 70.0, 69.5, 68.9, 40.5, 39.9; 19F NMR (500 MHz), CDCl3,
δ (ppm) −59.6; MS (ESI+): m/z 391.1 [M]+; elemental analysis
(%) for [C17H16F3FeN3O]: calc. C: 52.20, H: 4.12, N: 10.74;
found C: 52.25, H: 4.21, N: 10.59.
N-Methylferrocenyl,3-(trifluoromethyl)-1-phenyl-1H-pyrazole-
4-carboxylamide (complex 2). Yield 48% (57 mg). 1H NMR
(500 MHz), CDCl3, δ (ppm) 8.48 (s, 1H, PyH), 7.70 (d, 2H,
ArH), 7.50 (t, 2H, ArH), 7.41 (t, 1H, ArH), 6.33 (s, 1H, NH), 4.34
(d, 2H, CH2), 4.23 (br, 2H, Fc), 4.20 (s, 5H, Fc), 4.18 (br, 2H,
Fc); 13C NMR (500 MHz), CDCl3, δ (ppm) 160.2, 142.8, 139.2,
133.7, 130.4, 129.1, 120.6, 119.1, 100.9, 100.0, 98.1, 70.7, 40.2,
33.2; 19F NMR (500 MHz), CDCl3, δ (ppm) −59.7; MS (ESI+): m/z
453.1 [M]+; elemental analysis (%) for [C22H18F3FeN3O]: calc. C:
58.30, H: 4.00, N: 9.27; found C: 57.81, H: 3.90, N: 8.77.
N-Methylferrocenyl,1-methyl-5-phenoxy-3-(trifluoromethyl)-
1H-pyrazole-4-carboxylamide (complex 3). Yield 23% (29 mg).
Fig. 3 ROS level determination in SC upon treatment with complex 1a
and 1b; sedaxane (100 µM) was used for comparative purposes, H2O2
(10 µM) and Clotrimazole (5 µM) as a positive control.
Paper Dalton Transactions
6622 | Dalton Trans., 2016, 45, 6619–6626 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
M
ar
ch
 2
01
6.
 D
ow
nl
oa
de
d 
on
 0
8/
02
/2
01
7 
15
:3
4:
40
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1H NMR (500 MHz), CDCl3, δ (ppm) 7.38 (t, 2H, ArH), 7.20 (t,
1H, ArH), 6.21 (s, 1H, NH), 4.11 (m, 9H, Fc), 4.05 (s, 2H, CH2),
3.68 (s, 3H, CH3);
13C NMR (500 MHz), CDCl3, δ (ppm) 159.0,
156.1, 148.6, 131.2, 125.6, 119.9, 115.9, 105.9, 101.3, 100.2,
99.3, 98.1, 69.4, 39.3, 36.1; 19F NMR (500 MHz), CDCl3,
δ (ppm) −62.2; MS (ESI+): m/z 483.1 [M]+; elemental analysis
(%) for [C23H20F3FeN3O2]: calc. C: 57.16, H: 4.17, N: 8.70;
found C: 57.01, H: 4.09, N: 8.59.
N-Methylruthenocenyl,3-(trifluoromethyl)-1-methyl-1H-pyr-
azole-4-carboxylamide (complex 1b). Ruthenocene carboxyl-
aldheyde16 (130 mg, 0.5 mmol) was dissolved in 10 mL of
absolute ethanol. To this mixture was then added hydroxyl-
amine hydrochloride (64 mg, 1.5 mmol) and an excess of
NaOH (5 mmol). The resulting mixture was refluxed for 3 h
under a N2 atmosphere. The obtained ruthenocenyl oxyme was
extracted with CH2Cl2, washed with bidistilled water, dried on
MgSO4 and, after filtration, the organic solvent was evaporated
under reduced pressure. Ruthenocenyl oxyme was directly
used without further purification for the next synthetic step.
Ruthenocenyl oxyme was then dissolved in dry 5 mL of THF
and reduced to methylaminoferrocene in the presence of
LiAlH4 (190 mg, 5 mmol) under reflux conditions for 6 h
under a N2 atmosphere. The mixture was cooled down and
hydrolyzed with 20 mL of bidistilled water. Methylaminoruthe-
nocene was then extracted with diethylether. The combined
organic layers were then removed under reduced pressure.
3-(Trifluoromethyl)-1-methyl-1H-pyrazole-4-carboxylic acid
(0.50 mmol) was dissolved in dry DMF (2 mL) under a N2
atmosphere. This solution was added to a 1 mL solution of
N,N′-diisopropylethylamine (DIPEA, 1.5 mmol) and 1-[bis-
(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxid hexafluorophosphate (HATU) (1.5 mmol) in dry DMF.
The new solution was then stirred for 20 min at room tempera-
ture. Methylaminoruthenocene dissolved in 10 mL of dry DMF
was then added to the mixture which was then stirred in the
dark overnight. The solvent was evaporated using a high-
vacuum pump. The reddish oil was then purified by column
chromatography (silica, ethylacetate : hexane, 8 : 2, Rf = 0.75).
The fractions were collected and the solvent was removed
in vacuo to obtain a brownish powder. Yield 58%. 1H NMR
(500 MHz), CDCl3, δ (ppm) 7.91 (s, 1H, ArH), 6.10 (s, 1H, NH),
4.59 (m, 2H, RcH) 4.50 (m, 5H, RcH), 4.49 (m, 2H, RcH), 4.13
(d, 2H, CH2), 3.93 (s, 3H, CH3);
13C NMR (500 MHz), CDCl3,
δ (ppm) 160.6, 136.3, 122.7, 120.6, 117.9, 89.0, 71.2, 70.8, 70.5,
40.4, 39.4; 19F NMR (300 MHz), CDCl3, δ (ppm) −55.8; MS
(ESI+): m/z 438.1 [M + H]+, 896.1 [2M + Na]+; elemental analysis
(%) for [C17H16F3RuN3O]: calc. C: 46.79, H: 3.70, N: 9.63;
found C: 46.83, H: 3.73, N: 9.90.
Crystallographic data collections and structure refinements
Single-crystal X-ray diﬀraction data were collected at 183(1) K
on an Agilent Technologies SuperNova diﬀractometer for 1a–2
and on an Agilent Technologies Xcalibur Ruby area-detector
diﬀractometer for 3 using a single wavelength Enhance X-ray
source with Mo Kα radiation (λ = 0.71073 Å) for 1a and 3 or
with Cu Kα radiation (λ = 1.54184 Å) for 2 from a micro-focus
X-ray source, and an Oxford Instrument’s Cryojet XL cooler.
The selected suitable single crystal was mounted using poly-
butene oil on a flexible loop fixed on a goniometer head and
immediately transferred to the diﬀractometer. Pre-experiment,
data collection, data reduction and analytical absorption cor-
rection19 were performed with the program suite CrysAlisPro.19
Using Olex2,19 the structures were solved with the ShelXS9719
structure solution program using direct methods and refined
with the SHELXL201419 program package by full-matrix least-
squares minimization on F2. PLATON19 was used to check the
result of the X-ray analyses. All non-H atoms were anisotropi-
cally refined. All hydrogen positions were calculated after each
cycle of refinement using a riding model with C–H = 0.93 Å
and Uiso(H) = 1.2Ueq(C) for aromatic H atoms, with C–H =
0.97 Å and Uiso(H) = 1.2Ueq(C) for methylene H atoms, and
with C–H = 0.96 Å and Uiso(H) = 1.5Ueq(C) for methyl H atoms,
except for the amido H atoms which were freely refined. For
more details about the data collection and refinements para-
meters, see the Crystallographic Information files (ESI†).
Crystal data for C17H16F3FeN3O (1a) (M = 391.18 g mol
−1):
orthorhombic, space group Pbca (no. 61), a = 10.3579(2) Å, b =
8.72054(14) Å, c = 36.8998(7) Å, V = 3333.04(10) Å3, Z = 8, T =
183(1) K, μ(MoKα) = 0.946 mm−1, Dcalc = 1.559 g cm−3, 22 551
reflections measured (4.416° ≤ 2Θ ≤ 50.692°), 3034 unique
(Rint = 0.0293, Rsigma = 0.0172) which were used in all calcu-
lations. The final R1 was 0.0380 (I > 2σ(I)) and wR2 was 0.0929
(all data). Crystal data for C22H18F3FeN3O·CHCl3 (2) (M =
572.61 g mol−1): monoclinic, space group I2/a (no. 15), a =
10.6241(2) Å, b = 15.1983(4) Å, c = 29.6784(7) Å, β = 90.352(2)°,
V = 4792.03(19) Å3, Z = 8, T = 183(1) K, μ(CuKα) = 8.534 mm−1,
Dcalc = 1.587 g cm
−3, 16 614 reflections measured (5.956° ≤ 2Θ
≤ 136.496°), 4393 unique (Rint = 0.0432, Rsigma = 0.0284) which
were used in all calculations. The final R1 was 0.0370 (I > 2σ(I))
and wR2 was 0.0994 (all data). Crystal data for C23H20F3FeN3O2 (3)
(M = 483.27 g mol−1): triclinic, space group P1ˉ (no. 2), a =
9.4458(3) Å, b = 10.3520(4) Å, c = 11.0470(4) Å, α = 96.727(3)°,
β = 102.651(3)°, γ = 100.958(3)°, V = 1020.46(6) Å3, Z = 2, T =
183(1) K, μ(MoKα) = 0.793 mm−1, Dcalc = 1.573 g cm−3, 24870
reflections measured (4.534° ≤ 2Θ ≤ 61.016°), 6226 unique
(Rint = 0.0381, Rsigma = 0.0276) which were used in all calcu-
lations. The final R1 was 0.0344 (I > 2σ(I)) and wR2 was 0.0941 (all
data). CCDC 1433288 (for 1), 1433289 (for 2), and 1433290 (for 3)
contain the supplementary crystallographic data for this paper.
Biological evaluation
Cell culture. Human fibroblast (MRC-5) and retinal pigment
epithelial (RPE) cell lines were cultured in F-10 medium sup-
plemented with 10% fetal calf serum (FCS, Gibco), 100 U per
mL penicillin, 100 μg per mL streptomycin or DMEM medium
(Gibco) supplemented with 10% fetal calf serum (FCS, Gibco),
100 U per mL penicillin, and 100 μg per mL streptomycin,
respectively, at 37 °C and 6% CO2.
Yeast culture. Wild type Saccharomyces cerevisiae was freshly
inoculated and cultured in autoclaved YPD buﬀer containing
2% bacto peptone, 1% bacto yeast extract and 2% glucose anhy-
drous at 30 °C (Kuhner shaker Labtherm, Kuhner Switzerland).
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Cytotoxicity studies. Cytotoxicity studies of the eﬀect of
1ab–3 were performed by a fluorometric cell viability assay
using resazurin (Promocell GmbH).18 Briefly, one day before
treatment the cells were plated in triplicate in 96-well plates at
a density of 4 × 103 cells per well in 100 μL. Upon treating the
cells with increasing concentrations of the new sedaxicenes,
the cells were incubated for 48 h at 37 °C/6% CO2, the
medium was removed, and 100 μL of complete medium con-
taining resazurin (0.2 mg mL−1 final concentration) was
added. After 4 h of incubation at 37 °C/6% CO2, the fluo-
rescence of the highly red fluorescent resorufin product was
quantified at 590 nm emission with 540 nm excitation wave-
length using a SpectraMax M5 Microplate Reader. The results
were expressed as mean ± standard deviation error of indepen-
dent experiments.
Toxicity towards fungi. The activity of complex 1ab–3 on SC
was evaluated via a newly established colony formation assay.
Briefly, one day before treatment an aliquot of wild type SC
was inoculated in 5 mL YPD buﬀer solution (see above) and
incubated overnight at 30 °C. The fungal proliferation was
then quantified at 600 nm in a Cary60 UV/Vis (Agilent Techno-
logies). The SC was then seeded at diﬀerent concentrations of
the yeast (representing OD of 0.02 for mid-growth colony and
0.002 for low-growth colony) in 12-well plates containing a
2 mL growing terrain. The growing terrain was composed of
YPD containing 2% of agar, autoclaved and kept at 50 °C
(water bath, Kotterman AG). Just before use, the growing
terrain was treated with increasing concentrations of the new
sedaxicenes and poured in diﬀerent wells, before solidifica-
tion. The treated plates were loaded with SC and incubated for
24 h at 30 °C. The fungal colony formation was monitored
with an Alpha Digitec camera (Bucher Biotec) and the colony
density was calculated with AlphaImager software (v1.3.0.7)
with multiplex band analysis mode/single tool. A series of
blanks (with the terrain not seeded with SC), a negative
control (with the terrain seeded with SC and treated just
DMSO as vehicle) and Clotrimazole as a positive control were
performed. The results were expressed as mean ± standard
error of independent experiments.
ROS level determination. The evaluation of intracellular
ROS levels was performed following a method recently estab-
lished by our group and re-adapted for fungal cultures.18 The
ROS determination was detected by the use of 2′,7′-dichloro-
fluorescin diacetate (H2DCF-DA, Sigma-Aldrich), a cell-
permeable non-fluorescent probe which is hydrolyzed in cells
and, which upon oxidation turns to highly fluorescent 2′,7′
dichlorofluorescein.18 Briefly, an aliquot of SC was inoculated
in 5 mL YPD buﬀer one day before treatment and incubated at
30 °C under gentle shaking (180 rpm) in a Kuhner shaker
Labtherm incubator (Kuhner, Switzerland) overnight. The
culture was then diluted to an OD of 0.005, added with 100 µM
of 1a–1b and incubated for further 16 h. The YPD medium was
then replaced with fresh medium containing H2DCF-DA (final
concentration 20 µM) and further incubated for 1 h at 30 °C
under gentle shaking. The OD of the fungal growth was re-
measured, the suspension was plated at diﬀerent dilutions in
duplicate in a 96-well plate and the fluorescence was quanti-
fied at 530 nm emission with 488 nm excitation wavelength
using a SpectraMax M5 Microplate Reader. The results were
expressed as mean and standard deviation error of diﬀerent
independent experiments, corrected for the fungal population.
Sedaxane (100 µM) was used for comparative purposes and
H2O2 at a final concentration of 10 µM and Clotrimazole at a
final concentration of 5 µM as positive controls.
Conclusions
The invasiveness and aggressiveness of pathogenic fungi are
too often underestimated or even ignored and have not been
reflected in an adequate new drug output – the majority of the
benchmark products were discovered in the last century! Wor-
ryingly, pathogenic fungi have started to develop drug toler-
ance, defeating an increasing number of therapies. Because of
the incidence, resistance and health risk of fungi-related dis-
eases, the discovery of novel drugs or strategies to fight fungal
infections is highly necessary. In this article, we coupled a new
eﬀective fungicide, namely sedaxane, with ferrocenyl and ruthe-
nocenyl moieties. This strategy has already been successfully
employed in medicinal chemistry to increase the therapeutic
potential of the accepted drugs. More specifically, we syn-
thesised four new organometallic compounds (complexes 1a,
1b, 2 and 3). The complexes were fully characterized by
1H, 13C and 19F NMR spectroscopy, ESI-MS, elemental analysis
(deviation < 0.5%) and X-ray crystallography (for the ferrocene
derivatives 1a, 2 and 3). The four complexes were found to have
a very low or even no toxicity towards human immortalized
fibroblast or epithelial cells. This result is favourable in relation
to topical as well as systemic applications. Complex 1a, bearing
a methyl group on the pyrazole core, was found to have an anti-
fungal toxicity in the micromolar range contrary to 2 and 3,
which bear a phenyl or a phenoxy group on the pyrazole core,
respectively. This fact suggests that structural modifications,
which hinder the pyrazole ring of the compound, aﬀect drasti-
cally the overall activity. Strikingly, investigation of the ROS level
in SC upon treatment with 1a and its isostructural but not
redox-active ruthenocene analogue 1b evidenced an increase of
these noxious species for 1a but not for 1b. Moreover, it has to
be noted that the parent drug sedaxane was found to not have
any fungicidal profile and to not induce ROS formation under
the same experimental conditions. It can therefore be assumed
that the increase in mycotoxicity depends on the presence of the
ferrocenyl moiety and its redox activity. Altogether these data
represent a promising starting point for the development of new
potent metal-based antifungal agents.
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